Activity Details

1.25 AMA PRA Category 1 Credit(s)
Genetic Counselor CEUs
Released: June 3, 2019
Expires: June 2, 2020
1.25 hours to complete

Accredited By

Target Audience

U.S. geneticists and genetic counselors
International neurologists, pediatricians and geneticists

Learning Objectives

  • Explain the genetic aspects of SMA
  • Review the recessive nature of SMA
  • Discuss SMA carrier status
  • Discuss genetic screening recommendations
  • Explain status of newborn testing addition to screening panel
  • List states that have added newborn SMA testing
  • Explore the potential implications of gene replacement therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

Gene replacement therapy is gaining FDA approval in several therapeutic areas. In this roundtable discussion, three clinicians explain the different types of gene therapy and discuss risks and clinical trial results using spinal muscular atrophy (SMA) as an example.

Statement of Educational Need

Gene therapy is still a mystery to most clinicians. New therapies, such as gene therapy, prompt a reevaluation of the standards of care for patients with spinal muscular atrophy (SMA). Many clinicians have questions regarding SMA genetics.


  • A Patient’s Story
  • Genetics of SMA
  • Screening and Genetic Testing
  • Treatment Options
  • Gene Therapy 101
  • Gene Replacement Therapy in SMA
  • Panel Discussion of Common Questions


Wendy K. Chung, MD, PhD
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
  • No relevant financial relationships to disclose

Melissa A. Gibbons, MS, CGC
Assistant Professor
Department of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Aurora, CO
  • Melissa Gibbons, MS, CGC, serves on advisory boards for Sarepta and AveXis.

Vamshi K. Rao, MD
Attending Physician, Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
  • Vamshi Rao, MD, serves on the advisory board for AveXis and is a principal investigator for a clinical trial for NS Pharma.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselor CEUs
The National Society of Genetic Counselors (NSGC) has authorized The France Foundation to offer up to 0.1 CEUs or 1 Category 1 contact hour for the activity Are You Ready for Gene Replacement Therapy? Example from SMA. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving AMA PRA Category 1 Credit. The first 50 participants requesting NSGC CEUs are free. All others must submit $25 payment. Instructions will be sent with a link for payment within a month of completing the activity.
  • Review the activity objectives and CME/CE/CEU information.
  • Participate in the CME/CE/CEU activity.
  • Complete the CME/CE/CEU evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect his/her professional practice, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting CME or CE credit, your certificate of credit or certificate of participation will be immediately available for download.
    • If you are requesting NSGC CEU credit, The France Foundation will submit all documentation of activity completion to NSGC. Your CEU certificate will be issued by the end of the calendar year in which you complete the activity. Please note that your NSGC User ID is required to claim credit. Visit to find your user ID.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclosure of Unlabeled Use

TFF requires CME/CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.